The predictive capacity of biomarkers for clinical pulmonary oedema in patients with severe falciparum malaria is low: a prospective observational study.
Plasmodium falciparum
Club cell secretory protein
Interleukin-6
Interleukin-8
Krebs von den Lungen-6
Pulmonary oedema
Severe malaria
Soluble receptor of advanced glycation end-products
Surfactant protein-D
Tumour necrosis factor
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
24 Oct 2024
24 Oct 2024
Historique:
received:
08
07
2024
accepted:
12
10
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
Pulmonary oedema is a feared and difficult to predict complication of severe malaria that can emerge after start of antimalarial treatment. Proinflammatory mediators are thought to play a central role in its pathogenesis. An exploratory study was conducted to evaluate the predictive capacity of biomarkers for development of clinical pulmonary oedema in patients with severe falciparum malaria at two hospitals in Bangladesh. Plasma concentrations of interleukin-6 (IL-6), IL-8, tumour necrosis factor (TNF), soluble Receptor of Advanced Glycation End-products (sRAGE), surfactant protein-D (SP-D), club cell secretory protein (CC16), and Krebs von den Lungen-6 (KL-6) on admission were compared with healthy controls. Correlations between these biomarker and plasma lactate and Plasmodium falciparum histidine-rich protein 2 (PfHRP2) levels were evaluated. Receiver Operating Characteristic (ROC) curves were constructed to assess the predictive capacity for clinical pulmonary oedema of the biomarkers of interest. Of 106 screened patients with falciparum malaria, 56 were classified as having severe malaria with a mortality rate of 29%. Nine (16%) patients developed clinical pulmonary oedema after admission. Plasma levels of the biomarkers of interest were higher in patients compared to healthy controls. IL-6, IL-8, TNF, sRAGE, and CC16 levels correlated well with plasma PfHRP2 levels (r IL-6, IL-8, TNF, sRAGE, SP-D, CC16 and KL-6 cannot be used in predicting clinical pulmonary oedema in severe malaria patients.
Sections du résumé
BACKGROUND
BACKGROUND
Pulmonary oedema is a feared and difficult to predict complication of severe malaria that can emerge after start of antimalarial treatment. Proinflammatory mediators are thought to play a central role in its pathogenesis.
METHODS
METHODS
An exploratory study was conducted to evaluate the predictive capacity of biomarkers for development of clinical pulmonary oedema in patients with severe falciparum malaria at two hospitals in Bangladesh. Plasma concentrations of interleukin-6 (IL-6), IL-8, tumour necrosis factor (TNF), soluble Receptor of Advanced Glycation End-products (sRAGE), surfactant protein-D (SP-D), club cell secretory protein (CC16), and Krebs von den Lungen-6 (KL-6) on admission were compared with healthy controls. Correlations between these biomarker and plasma lactate and Plasmodium falciparum histidine-rich protein 2 (PfHRP2) levels were evaluated. Receiver Operating Characteristic (ROC) curves were constructed to assess the predictive capacity for clinical pulmonary oedema of the biomarkers of interest.
RESULTS
RESULTS
Of 106 screened patients with falciparum malaria, 56 were classified as having severe malaria with a mortality rate of 29%. Nine (16%) patients developed clinical pulmonary oedema after admission. Plasma levels of the biomarkers of interest were higher in patients compared to healthy controls. IL-6, IL-8, TNF, sRAGE, and CC16 levels correlated well with plasma PfHRP2 levels (r
CONCLUSIONS
CONCLUSIONS
IL-6, IL-8, TNF, sRAGE, SP-D, CC16 and KL-6 cannot be used in predicting clinical pulmonary oedema in severe malaria patients.
Identifiants
pubmed: 39448997
doi: 10.1186/s12936-024-05142-3
pii: 10.1186/s12936-024-05142-3
doi:
Substances chimiques
Biomarkers
0
HRP-2 antigen, Plasmodium falciparum
0
Cytokines
0
Antigens, Protozoan
0
Protozoan Proteins
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
320Subventions
Organisme : Wellcome Trust
ID : 220211
Pays : United Kingdom
Informations de copyright
© 2024. The Author(s).
Références
WHO. World malaria report 2022. Geneva: World Health Organization; 2022.
Taylor WR, Hanson J, Turner GD, White NJ, Dondorp AM. Respiratory manifestations of malaria. Chest. 2012;142:492–505.
doi: 10.1378/chest.11-2655
pubmed: 22871759
White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet. 2014;383:723–35.
doi: 10.1016/S0140-6736(13)60024-0
pubmed: 23953767
World Health Organization. Severe malaria. Trop Med Int Health. 2014;19(Suppl 1):1–131.
Hanson JP, Lam SW, Mohanty S, Alam S, Pattnaik R, Mahanta KC, et al. Fluid resuscitation of adults with severe falciparum malaria: effects on acid–base status, renal function, and extravascular lung water. Crit Care Med. 2013;41:972–81.
doi: 10.1097/CCM.0b013e31827466d2
pubmed: 23324951
Ishioka H, Plewes K, Pattnaik R, Kingston HWF, Leopold SJ, Herdman MT, et al. Associations between restrictive fluid management and renal function and tissue perfusion in adults with severe falciparum malaria: a prospective observational study. J Infect Dis. 2020;221:285–92.
doi: 10.1093/infdis/jiz449
pubmed: 31504666
Ware LB, Koyama T, Zhao Z, Janz DR, Wickersham N, Bernard GR, et al. Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit Care. 2013;17:R253.
doi: 10.1186/cc13080
pubmed: 24156650
pmcid: 4056313
Terpstra ML, Aman J, van Nieuw Amerongen GP, Groeneveld AB. Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis*. Crit Care Med. 2014;42:691–700.
doi: 10.1097/01.ccm.0000435669.60811.24
pubmed: 24158164
van der Zee P, Rietdijk W, Somhorst P, Endeman H, Gommers D. A systematic review of biomarkers multivariately associated with acute respiratory distress syndrome development and mortality. Crit Care. 2020;24:243.
doi: 10.1186/s13054-020-02913-7
pubmed: 32448370
pmcid: 7245629
Serpa Neto A, Campos PP, Hemmes SN, Bos LD, Bluth T, Ferner M, et al. Kinetics of plasma biomarkers of inflammation and lung injury in surgical patients with or without postoperative pulmonary complications. Eur J Anaesthesiol. 2017;34:229–38.
doi: 10.1097/EJA.0000000000000614
pubmed: 28187051
Tran TH, Day NP, Nguyen HP, Nguyen TH, Tran TH, Pham PL, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med. 1996;335:76–83.
doi: 10.1056/NEJM199607113350202
pubmed: 8649493
Hanson J, Lam SW, Mohanty S, Alam S, Hasan MM, Lee SJ, et al. Central venous catheter use in severe malaria: time to reconsider the World Health Organization guidelines? Malar J. 2011;10:342.
doi: 10.1186/1475-2875-10-342
pubmed: 22082224
pmcid: 3228715
Matthay MA, Arabi Y, Arroliga AC, Bernard G, Bersten AD, Brochard LJ, et al. A new global definition of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2024;209:37–47.
doi: 10.1164/rccm.202303-0558WS
pubmed: 37487152
Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB, et al. Comparison of the SpO
doi: 10.1378/chest.07-0617
pubmed: 17573487
Shapiro BA, Peruzzi WT, Templin R. Clinical application of blood gases. 5th ed. Chicago: Mosby; 1994.
WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization; 2010.
Dondorp AM, Desakorn V, Pongtavornpinyo W, Sahassananda D, Silamut K, Chotivanich K, et al. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med. 2005;2:e204.
doi: 10.1371/journal.pmed.0020204
pubmed: 16104831
pmcid: 1188247
van der Woude MC, Bormans L, van der Horst RP, Sosef MN, Belgers HJ, Hemmes SN, et al. Pulmonary levels of biomarkers for inflammation and lung injury in protective versus conventional one-lung ventilation for oesophagectomy: a randomised clinical trial. Eur J Anaesthesiol. 2020;37:1040–9.
doi: 10.1097/EJA.0000000000001126
pubmed: 31789965
Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334–49.
doi: 10.1056/NEJM200005043421806
pubmed: 10793167
Day NP, Hien TT, Schollaardt T, Loc PP, Chuong LV, Chau TT, et al. The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis. 1999;180:1288–97.
doi: 10.1086/315016
pubmed: 10479160
Uchida T, Shirasawa M, Ware LB, Kojima K, Hata Y, Makita K, et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med. 2006;173:1008–15.
doi: 10.1164/rccm.200509-1477OC
pubmed: 16456142
pmcid: 2662912
Kropski JA, Fremont RD, Calfee CS, Ware LB. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest. 2009;135:1440–7.
doi: 10.1378/chest.08-2465
pubmed: 19188556
pmcid: 2716712
Determann RM, Millo JL, Waddy S, Lutter R, Garrard CS, Schultz MJ. Plasma CC16 levels are associated with development of ALI/ARDS in patients with ventilator-associated pneumonia: a retrospective observational study. BMC Pulm Med. 2009;9:49.
doi: 10.1186/1471-2466-9-49
pubmed: 19958527
pmcid: 2794841